Geraniol attenuates α-synuclein expression and neuromuscular impairment through increase dopamine content in MPTP intoxicated mice by dose dependent manner

Biochemical and Biophysical Research Communications

Volumn 440, Issue 4, 2013, Pages 664-670

  Rekha, Karamkolly R ^a   Selvakumar, Govindasamy P ^a   Santha, Karunanithi ^a   Inmozhi Sivakamasundari, Ramu ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

Degeneration; Geraniol; MPTP; Neuroprotective; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DOPAMINE; GERANIOL; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROMUSCULAR DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; RNA EXTRACTION; WESTERN BLOTTING;

MUS;

EID: 84887090703     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.09.122     Document Type: Article

References (52)

1. H. Bernheimer, W. Birkmayer, O. Hornykiewicz, K. Jellinger, and F. Seitelberger Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations J. Neurol. Sci. 20 1973 415 455
2. N.B. Chauhan, G.J. Siegel, and J.M. Lee Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain J. Chem. Neuroanat. 21 2001 277 288
3. H. Braak, and K. Del Tredici Invited article: nervous system pathology in sporadic Parkinson disease Neurology 70 2008 1916 1925
4. J. Zhou, M. Broe, Y. Huang, J.P. Anderson, W.P. Gai, E.A. Milward, M. Porritt, D. Howells, A.J. Hughes, X. Wang, and G.M. Halliday Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease Acta Neuropathol. 121 2011 695 704
5. H. Yokoyama, H. Kuroiwa, and R. Yano Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease Neurol. Sci. 29 2008 293 301
6. W.J. Brooks, M.F. Jarvis, and G.C. Wagner Astrocytes as a primary locus for the conversion MPTP into MPP+ J. Neural Transm. 76 1989 1 12
7. R.J. Smeyne, and V. Jackson-Lewis The MPTP model of Parkinson's disease Brain Res. Mol. Brain Res. 134 2005 57 66
8. C.W. Olanow, and W.G. Tatton Etiology and pathogenesis of Parkinson's disease Annu. Rev. Neurosci. 22 1999 123 144
9. S. Przedborski, and V. Jackson-Lewis Mechanisms of MPTP toxicity Mov. Disord. 13 1998 35 38
10. S. Przedborski, Q. Chen, M. Vila, B.I. Giasson, R. Djaldatti, S. Vukosavic, J.M. Souza, V. Jackson-Lewis, V.M.Y. Lee, and H. Ischiropoulos Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease J. Neurochem. 76 2001 637 640
11. B.I. Giasson, J.E. Duda, I.V.J. Murray, Q. Chen, J.M. Souza, H.I. Hurtig, H. Ischiropoulos, J.Q. Trojanowski, and V.M.Y. Lee Oxidative damage linked to neurodegeneration by selectivea-synuclein nitration in synucleinopathy lesions Science 290 2000 985 989
12. L.J. Hsu, Y. Sagara, A. Arroyo, E. Rockenstein, A. Sisk, M. Mallory, J. Wong, T. Takenouchi, M. Hashimoto, and E. Masliah Alpha synuclein promotes mitochondrial deficit and oxidative stress Am. J. Pathol. 157 2000 401 410
13. Y. Levites, O. Weinreb, G. Maor, M.B. Youdim, and S. Mandel Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic neurodegeneration J. Neurochem. 78 2001 1073 1082
14. S. Li, and X.P. Pu Neuroprotective effect of kaempferol against a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease Biol. Pharm. Bull. 34 2011 1291 1296
15. A. Kreisler, P. Gele, J.F. Wiart, M. Lhermitte, A. Destee, and R. Bordet Lipid lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezofibrate and HMG-CoA reductase inhibitors do not Brain Res. 1135 2007 77 84
16. M. Tiwari, and P. Kakkar Plant derived antioxidants - geraniol and camphene protect rat alveolar macrophages against t-BHP induced oxidative stress Toxicol. In Vitro 23 2009 295 301
17. S. Robinson, P. Freeman, C. Moore, J.C. Touchon, L. Krentz, and C.K. Meshul Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function Exp. Neurol. 180 2003 73 86
18. K.R. Rekha, G.P. Selvakumar, S. Sethupathy, K. Santha, and R. Inmozhi Sivakamasundari geraniol ameliorates the motor behavior and neurotrophic factors inadequacy in MPTP-induced mice model of Parkinson's Disease J. Mol. Neurosci. 2013 10.1007/s12031-013-0074-9
19. H. Hayashita-Kinoh, M. Yamada, T. Yokota, Y. Mizuno, and H. Mochizuki Down-regulation of a-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model Biochem. Biophys. Res. Commun. 341 2006 1088 1095
20. J.L. Tillerson, and G.W. Miller Grid performance test to measure behavioral impairment in the MPTP-treated mouse model of Parkinsonism J. Neurosci. Methods 123 2003 189 200
21. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the Folin phenol reagent J. Biol. Chem. 193 1951 265 275
22. D. Muralikrishnan, and K.P. Mohanakumar Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice FASEB J. 12 1998 905 912
23. A. Anandhan, U. Janakiraman, and T. Manivasagam Theaflavin ameliorates behavioral deficits, biochemical indices and monoamine transporters expression against subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease Neuroscience 218 2012 257 267
24. P.A. Kingston, F. Zufall, and C.J. Barnstable Rat hippocampal neurons express genes for both rod retinal and olfactory cyclic nucleotide-gated channels: novel targets for cAMP/cGMP function Proc. Natl. Acad. Sci. USA 93 1996 10440 10445
25. E.M. Szego, E. Gerhardt, P. Kermer, B. Jorg, and J.B. Schulz A30Pα-synuclein impairs dopaminergicfiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice Neurobiol. Dis. 45 2012 591 600
26. R.E. Heikkila, and P.K. Sonsalla The MPTP-treated mouse as a model of parkinsonism: how good is it? Neurochem. Int. 20 1992 299S 303S
27. M. Sedelis, K. Hofele, G.W. Auburger, S. Morgan, J.P. Huston, and R.K.W. Schwarting MPTP susceptibility in the mouse: behavioral, neurochemical and histological analysis of gender and strain differences Behav. Genet. 30 2000 171 182
28. C. Zhou, Y. Huang, and S. Przedborski Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance Ann. N. Y. Acad. Sci. 1147 2008 93 104
29. W. Luczaj, and E. Skrzydlewska Antioxidant properties of black tea in alcohol intoxication Food Chem. Toxicol. 42 2004 2045 2051
30. R.N. Kalaria, M.J. Mitchell, and S.I. Harik Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity Proc. Natl. Acad. Sci. USA 84 1987 3521 3525
31. S. Yoshihara, and S. Ohta Involvement of hepatic aldehyde oxidase in conversion of 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+) to 1-methyl-4-phenyl-5,6-dihydro-2-pyridone Arch. Biochem. Biophys. 360 1998 93 98
32. W. Birkmayer, J. Knoll, P. Riederer, M.B. Youdim, V. Hars, and J. Marton Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a long term study J. Neural. Transm. 64 1985 113 127
33. C.W. Shults Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease, Parkinson Study Group Acta Neurol. Scand. Suppl. 146 1993 36 42
34. H. Bernheimer, and O. Hornykiewicz Decreased homovanillic acid concentration in the brain in Parkinsonian subjects as an expression of a disorder of central dopamine metabolism Klein Wochenschr. 43 1965 711 715
35. H. Ehringer, and O. Hornykiewic Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system Klin Wochenschr. 38 1960 1236 1239
36. K.R. Shepherd, E.S. Lee, L. Schmued, Y. Jiao, S.F. Ali, E.T. Oriaku, N.S. Lamango, K.A. Soliman, and C.G. Charlton The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice Pharmacol. Biochem. Behav. 83 2006 349 359
37. N.R. Goldberg, A.K. Haack, N.S. Lim, O.K. Janson, and C.K. Meshul Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Neuroscience 180 2011 256 271
38. V. Jackson-Lewis, M. Jakowec, R.E. Burke, and S. Przedborski Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Neurodegeneration 4 1995 257 269
39. W.D. Rausch, Y. Hirata, T. Nagatsu, P. Riederer, and K. Jellinger Tyrosine hydroxylase activity in caudate nucleus from Parkinson's disease: effects of iron and phosphorylating agents J. Neurochem. 50 1988 202 208
40. J.M. George, H. Jin, W.S. Woods, and D.F. Clayton Characterization of a novel protein regulated during the critical period for song learning in the zebra fish Neuron 15 1995 361 372
41. N.G. Kholodilov, M. Neystat, T.F. Oo, S.E. Lo, K.E. Larsen, D. Kulzer, and R.E. Burke Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury J. Neurochem. 73 1999 2586 2599
42. H. Van der Putten, K.H. Wiederhold, A. Proust, S. Baribieri, C. Misty, S. Danner, S. Kauffmann, K. Hoefele, and M.A. Ruegg Neuropathology in mice expressing human alpha-synuclein J. Neurosci. 20 2000 6021 6029
43. J.J. Cohen, and R.C. Duke Glucocorticoid activation of a calcium dependent endonuclease in thymocyte nuclei leads to cell death J. Immunol. 132 1984 38 42
44. J. Galon, D. Franchimont, N. Hiroi, G. Frey, A. Boettnger, M. Ehrhart-Bornstein, J.J. O'Shea, G.P. Chrousos, and S.R. Bornstein Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells FASEB J. 16 2002 61 71
45. C.A. da Costa, K. Ancolio, and F. Checler Wild-type but not Parkinson's disease-related ala-53 → Thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli J. Biol. Chem. 275 2000 24065 24069
46. J.H. Seo, J.C. Rah, S.H. Choi, J.K. Shin, K. Min, H.S. Kim, C.H. Park, S. Kim, E. Kim, and S.H. Lee Alpha-Synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt pathway FASEB J. 16 2002 1826 1828
47. A. Zourlidou, M.D. Payne Smith, and D.S. Latchman Modulation of cell death by alpha-synuclein is stimulus-dependent in mammalian cells Neurosci. Lett. 340 2003 234 238
48. J.H. Lu, M.T. Ardah, S.S. Durairajan, L.F. Liu, L.X. Xie, and W.F. Fong Baicalein inhibits formation of α-synuclein oligomers within living cells and prevents Aβ peptide fibrillation and oligomerisation ChemBioChem 12 2011 615 624
49. M. Zhu, S. Rajamani, J. Kaylor, S. Han, F. Zhou, and A.L. Fink The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils J. Biol. Chem. 279 2004 26846 26857
50. D.H. Lee, C.S. Kim, and Y.J. Lee Astaxanthin protects against MPTP/MPP+-induced mitochondrial dysfunction and ROS production in vivo and in vitro Food Chem. Toxicol. 49 2011 271 280
51. Y. Cheng, G. He, X. Mu, T. Zhang, X. Li, and J. Hu Neuroprotective effect of baicalein against MPTP neurotoxicity: behavioral, biochemical and immunohistochemical profile Neurosci. Lett. 441 2008 16 20
52. X. Mu, G.R. He, X. Yuan, X.X. Li, and G.H. Du Baicalein protects the brain against neuron impairments induced by MPTP in C57BL/6 mice Pharmacol. Biochem. Behav. 98 2011 286 291